Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

Lise Hoejberg, Lars Bastholt, Julia S Johansen, Ib Jarle Christensen, Julie Gehl, Henrik Schmidt

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P
OriginalsprogEngelsk
TidsskriftMelanoma Research
Vol/bind22
Udgave nummer4
Sider (fra-til)287-93
Antal sider7
ISSN0960-8931
DOI
StatusUdgivet - 2012

Fingeraftryk Dyk ned i forskningsemnerne om 'Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma'. Sammen danner de et unikt fingeraftryk.

Citationsformater